Core Viewpoint - Jilin Aodong has evolved into a holding group company driven by both the pharmaceutical industry and financial capital, aiming to rejuvenate traditional Chinese medicine in modern society through innovation [6][13]. Company Development - Founded in 1957, Jilin Aodong has undergone significant transformations, including the establishment of a pharmaceutical factory in 1981, a shareholding reform in 1993, and its listing on the Shenzhen Stock Exchange in 1996 [6]. - The company has developed a comprehensive industrial chain in the pharmaceutical sector, integrating cultivation, research, production, testing, and sales [7]. Product Innovation - Jilin Aodong's core product, "Anshen Bnuna Liquid," has been a market leader for over 40 years, with a market share of 60% to 70% in its category, generating over 700 million yuan in annual sales [7]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the listing of 525 traditional Chinese medicine formula granules [9]. Technological Advancements - The company has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [10]. - The production process has transitioned to a fully automated system, enhancing efficiency and precision in drug manufacturing [10]. Market Expansion - Jilin Aodong is expanding into the health industry, producing over 200 health products, with some individual products generating over 1 million yuan in annual sales [11]. - The company is also investing in financial sectors, with a reported investment income of 1.206 billion yuan in the first half of 2025, a 53.67% increase year-on-year [12]. Financial Performance - In the first half of 2025, Jilin Aodong achieved a net profit of 1.282 billion yuan, a significant increase of 138.44% compared to the previous year [12]. - The company's total assets reached 34.151 billion yuan, with a debt-to-asset ratio of 11.54%, indicating a strong financial position [12]. Social Responsibility - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has contributed to local economic development through agricultural projects, generating 7.76 billion yuan in output value over the past decade [12].

Core Viewpoint - Jilin Aodong aims to transform traditional Chinese medicine into a modern enterprise through innovation and sustainable development, establishing itself as a leading pharmaceutical company with a dual focus on "pharmaceutical health + financial capital" [2][9]. Group 1: Company History and Development - Jilin Aodong has evolved from a state-owned deer farm established in 1957 to a publicly listed holding company, with significant milestones including the founding of a pharmaceutical factory in 1981 and its listing on the Shenzhen Stock Exchange in 1996 [2]. - The company has developed a comprehensive industrial chain in deer product processing, leveraging over 60 years of experience in breeding deer and achieving GAP certification for its breeding base [3]. Group 2: Product and Market Position - Jilin Aodong's core product, "Anshen Bunan Liquid," has been a market leader for over 40 years, holding a 60% to 70% market share in its category and generating over 700 million yuan in annual sales [3][8]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the registration of 525 traditional Chinese medicine formula granules, leading in registration numbers in Jilin Province [5]. Group 3: Innovation and Technology - Jilin Aodong has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [6]. - The company is embracing digital transformation, moving from experience-based production to data-driven processes, enhancing efficiency and product quality [6]. Group 4: Financial Performance - In the first half of the year, Jilin Aodong reported a net profit of 1.282 billion yuan, a significant increase of 138.44% year-on-year, with total assets reaching 34.151 billion yuan, up 3.48% from the beginning of the year [8]. - The company maintains a low debt ratio of 11.54%, indicating strong financial health within the industry [8]. Group 5: Social Responsibility and Community Engagement - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has created significant economic value for local communities through initiatives in ginseng and deer farming, generating 7.76 billion yuan in output value over the past decade [9]. - The company emphasizes its commitment to reinvesting profits into its pharmaceutical core business to support research, production upgrades, and market expansion [9].